Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
7 evidence topics · 15 sources
Summary
Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment; Sanofi states that, in people with CIDP who respond, about 70% of the response is considered incomplete. Approximately two-thirds of patients need long-term intravenous immunoglobulin, and in a US claims analysis 62% of immunoglobulin users were chronic users during the first year after the index date. Biomarkers of disease activity are lacking: in a withdrawal trial, 41% of participants withdrawn from intravenous immunoglobulin remained stable for 24 weeks, compared with 58% who continued it, and the lack of biomarkers can lead to potential overtreatment. After plasma exchange, 8 of 12 responders relapsed within 7 to 14 days of stopping. About 30% of survey respondents receiving intravenous immunoglobulin missed school or work because of infusions, and subcutaneous immunoglobulin typically requires administration once or twice a week. The Gamunex-C prescribing information carries a boxed warning for thrombosis, renal dysfunction, and acute renal failure, and states that renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous products in predisposed patients; observational studies indicate that corticosteroids carry a long-term risk of serious side effects.
Non-response and incomplete response to available treatments
“Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term dependence on immunoglobulin
“Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients who used Ig, 62% ( n = 1,113) were chronic and 38% ( n = 690) were intermittent users during the 1-year post-index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No biomarker of ongoing need for treatment, and overtreatment
“Biomarkers for disease activity are lacking, making the need for ongoing treatment difficult to assess, leading to potential overtreatment and high health-care costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the intravenous immunoglobulin withdrawal group, 41% remained stable for 24 weeks, compared to 58% in the intravenous immunoglobulin continuation group (−17%; 95% CI −39 to 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the intravenous immunoglobulin withdrawal group, 28% remained stable at the end of the extension phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“45/125 individuals met criteria for clinical stability, with median age 58 years, I‐RODS 37/48, MRC‐SS 69/70 and annual treatment costs £107 000/person.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“12 of 36 (33.3%) consented to cessation trial and eight of those (66.7%) remained stable off treatment for ≥ 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of infusions
“IVIg was associated with venous access issues and work/school absenteeism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 30% of respondents in each group that received IVIg missed school or work because of the infusions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCIG has fewer systemic adverse reactions than IVIG and can be administered at home by patients or caregivers, 8 but typically requires more frequent infusions, such as administration once or twice a week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (standard deviation) infusion duration was 135.5 (62.8) minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote